Xeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street Zen

Xeris Biopharma (NASDAQ:XERS) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Separately, Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Xeris Biopharma Price Performance

Shares of XERS stock opened at $7.93 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $10.08. The stock has a market cap of $1.37 billion, a P/E ratio of -72.09 and a beta of 0.66. The company has a 50 day simple moving average of $7.68 and a two-hundred day simple moving average of $6.79.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. The firm had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. On average, research analysts expect that Xeris Biopharma will post 0.03 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the sale, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. This represents a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares in the company, valued at approximately $13,442,530.52. This represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 266,499 shares of company stock valued at $1,996,417 over the last three months. 4.35% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Xeris Biopharma during the second quarter worth about $115,042,000. Pallas Capital Advisors LLC acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $88,000. Deutsche Bank AG purchased a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $4,193,000. Rice Hall James & Associates LLC purchased a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $2,382,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $282,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.